Over the last decade, our understanding of metabolism in the context of cancer has evolved greatly. It is now evident that altered cellular metabolism is an integral effector of tumorigenesis that is intricately intertwined with cell signaling as well as genetic and epigenetic regulation of diverse tumor programs. Recognizing the dysregulation of cellular metabolism as an important aspect of tumor function has offered new potential direction to seek clinical benefit by providing targets for the development of novel therapeutics. To-date, several small molecule inhibitors that target tumor or immune cell metabolism are being explored in active clinical trials as either preventive, stand-alone, or adjuvant therapies for various malignancies. Thus, identifying critical metabolic vulnerabilities in pre-neoplastic cells, cancer cells, and immune cells has direct and timely relevance for developing additional treatment and preventative strategies against cancer.
The goals of this Research Topic are to highlight advances in our understanding of aberrant cancer cell and immune cell metabolism, its impact on the tumor microenvironment, and to identify metabolic dependencies that can be targeted for anti-cancer treatment alone or in combination with other treatment modalities.
We are soliciting Original Research Articles as well as Reviews to contribute to this Research Topic. Themes of interest include, but are not limited to:
- Aberrant metabolic pathways enriched in cancer cells
- Metabolic dependencies in cancer
- Alterations in tumor metabolism and its impact on the tumor microenvironment with emphasis on the tumor immunophenotype
- Cancer sub-classification based on metabolic signatures
- Understanding and targeting immuno-onco metabolism
- Novel therapeutics targeting tumor metabolism
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Over the last decade, our understanding of metabolism in the context of cancer has evolved greatly. It is now evident that altered cellular metabolism is an integral effector of tumorigenesis that is intricately intertwined with cell signaling as well as genetic and epigenetic regulation of diverse tumor programs. Recognizing the dysregulation of cellular metabolism as an important aspect of tumor function has offered new potential direction to seek clinical benefit by providing targets for the development of novel therapeutics. To-date, several small molecule inhibitors that target tumor or immune cell metabolism are being explored in active clinical trials as either preventive, stand-alone, or adjuvant therapies for various malignancies. Thus, identifying critical metabolic vulnerabilities in pre-neoplastic cells, cancer cells, and immune cells has direct and timely relevance for developing additional treatment and preventative strategies against cancer.
The goals of this Research Topic are to highlight advances in our understanding of aberrant cancer cell and immune cell metabolism, its impact on the tumor microenvironment, and to identify metabolic dependencies that can be targeted for anti-cancer treatment alone or in combination with other treatment modalities.
We are soliciting Original Research Articles as well as Reviews to contribute to this Research Topic. Themes of interest include, but are not limited to:
- Aberrant metabolic pathways enriched in cancer cells
- Metabolic dependencies in cancer
- Alterations in tumor metabolism and its impact on the tumor microenvironment with emphasis on the tumor immunophenotype
- Cancer sub-classification based on metabolic signatures
- Understanding and targeting immuno-onco metabolism
- Novel therapeutics targeting tumor metabolism
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
